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Abstract
Background: Several tumour necrosis factor (TNF) based therapeutics have already been approved for human use
and several others are emerging. Therefore, we determined the mRNA expression levels of the TNF superfamily
ligands (TNFSF) – e.g. TNF-α, lymphotoxin (LT)-α, LT-β, Fas-L (CD95-L), TNF-related apoptosis-inducing ligand (TRAIL),
TNF-related weak inducer of apoptosis (TWEAK), 4-1BBL, OX40-L (CD252) and amyloid precursor protein (APP) in
healthy human and mouse solid organs.
Methods: We used quantitative real time-PCR to analyse mRNA expression levels of TNFSF ligands. Murine models
of acute ischemic renal injury, chronic oxalate nephropathy, and immune complex glomerulonephritis were used.
Renal injury was assessed by PAS staining, and infiltrating immune cells were analysed by immunohistochemistry.
Data was analysed using non-parametric ANOVA (non-parametric; Kruskal-Wallis test).
Results: We observed significant differences in the mRNA expression levels of TNFSF ligands in human and mouse
solid organs. Furthermore, we determined their mRNA expressions during acute and chronic kidney injuries in mice.
Our data demonstrate that the mRNA expression levels of TNFSF vary depending on the type of tissue injury – for
example, acute ischemic renal injury, chronic crystalline nephropathy, and immune complex glomerulonephritis. In
addition, we observed that mRNA expressions of TNFSF ligands are differentially regulated during the course of a
transient ischemic renal injury (IRI) and chronic kidney modelling. We observed that TNF-α, LT-β, and 4-1BBL were
significantly upregulated during the progression of IRI and crystal-induced chronic kidney disease (CKD), whereas
only 4-1BBL and TNF-α were significantly upregulated and LT-β was significantly downregulated during the
progression of immune complex glomerulonephritis. The mRNA expression of Fas-L was higher during IRI whereas
it decreased in a time dependent manner during the progression of crystal-induced CKD.
Conclusion: We conclude that the injury- and species-specific differences of TNFSF ligands must be considered in
order to avoid the misinterpretation and wrong conclusions during data extrapolation between species.
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Background
The potential of tumor necrosis factor (TNF) as a thera-
peutic target was exploited and has been well characterized
in various diseases soon after its discovery in 1975 [1, 2].
Until today, research in this field unveiled the existence of
19 TNF superfamily (TNFSF) proteins that signal through
29 receptors [3]. The TNFSF members are expressed widely
and play major roles in immune responses, inflammation,
cell homeostasis, and tissue repair [4, 5]. In addition, they
also contribute to disease pathogenesis, and therefore, are
also referred as “double-edged swords” [3]. Most of the
TNFSF members are type II transmembrane proteins, while
some can be secreted proteins with biological activity [6, 7].
Originally, macrophages were reported as a source of TNF
[1]. However, later on, a cytokine lymphotoxin (LT), which
has similar cytotoxic effects like TNF, was reported to be
secreted by B lymphocytes [8]. In 1984, the homology be-
tween TNF and LT was unveiled when they were purified
to homogeneity and their amino acid sequences were
determined [9, 10]. This initiated the hunt for more TNF-
like proteins leading to the discovery of 19 TNFSF ligands
until today [3].
The TNFSF ligands have C-terminal TNF homolog do-
main facilitating self-trimerization and receptor binding.
The TNF-receptor superfamily has two domains consis-
ting of an extracellular domain for ligand binding and a
cytoplasmic tail domain with adaptor proteins for signal
cascade activation [6, 7]. After binding to the respective
receptors, all members of the TNFSF activate pathways
that involve NF-ĸB, JUN N-terminal kinase (JNK), p42/44
mitogen-activated protein kinase (MAPK), p38 MAPK
and generation of reactive oxygen species (ROS) that or-
chestrate the pleiotropic effects of TNFSF ligands [11].
A huge amount of research on TNFSF ligands is con-
ducted in mice and the observations are often extrapo-
lated to human conditions. However, several discrepancies
in organ-specific expression levels of pattern recognition
receptors (PRRs), C-type lectin receptors (CLRs), TLR
accessory molecules as well as regulated necrosis-related
molecules, between species has already been reported
[12–18]. Therefore, we hypothesized that similar organ-
and species-specific differences might exist in TNFSF li-
gands expressions, and hence, determined their mRNA
expression profiles in human and mice organs. Further-
more, we checked their expression profiles in murine
acute tissue injury and chronic (progressive and immune
complex-mediated) tissue remodeling.
Methods
Human solid organ cDNA preparation
Total RNA from healthy human solid organ were pur-
chased from Clontech, Mountain View, CA. From each
individual sample, an equal amount of total RNA was used
as a template in cDNA preparation using Superscript II
(Invitrogen). As only a single pool was available for each
organ, no studies on biological replicates allowing statis-
tics could be performed. However, we used technical trip-
licates of each pooled sample. Usage of human solid organ
RNA samples obeys the purchase and import of Clontech
local laws and regulations.
Mouse solid organ cDNA preparation for qRT-PCR
experiments
Ten-twelve weeks old, adult C57BL/6 N male mice were
purchased from Charles River, Sulzfeld, Germany. Group of
five mice in a cage were housed in specific pathogen-free
conditions with ad libitum food and water. Mice were sacri-
ficed under general anesthesia by cervical dislocation. From
freshly collected tissues, RNA was isolated as described
[16]. Briefly, all organs immediately after harvest were
placed in RNA later solution and RNA was isolated with an
equal amount of tissue mass using Pure Link RNA Mini
Kit (Ambion, Germany) according to the manufacture in-
structions. All RNA samples were subjected to DNAse
enzyme treatment and additional washing steps were per-
formed to remove traces of DNAse. A NanoDrop 1000
Spectrophotometer was used to estimate the RNA concen-
trations, only samples with absorbance 260/280 between
1.95 and 2.05 were considered as pure RNA. The integrity
of the total RNA was determined by electrophoresis on 2%
(w/v) agarose gels as described. Further, cDNA was tran-
scribed using 1 μg of RNA as described before [16]. Briefly,
1 μg RNA was mixed with cDNA master mix (including
DTT, dNTPS, Rnasin, Acrylamide, Hexanucleotide and
Superscript II), and incubated for 1 h 30 min at 42 °C.
Supercript was inactivated by incubating at 90 °C for 5 min
and cDNA was stored at −20 °C until further use.
Animal studies
Renal Ischemic injury model: Groups of seven to eight
week old C57BL/6 mice (n = 5–10) under anesthesia
underwent unilateral renal pedicle clamping for 35 min
followed by reperfusion for 24 h, 5 days and 10 days as a
model of ischemia-reperfusion as described [19–21].
Throughout the procedure, body temperatures were main-
tained at 37 °C using a heating plate (Kleintier-OP-Tisch
M12511, Medax GmbH, Germany) and an egg breeding
device (Octagon 20 Advance, Brinsea products Ltd., UK).
Injured and contralateral kidneys were harvested for RNA
isolation and histology analysis. Contralateral kidneys
served as internal control kidneys. Chronic oxalate ne-
phropathy model was developed by feeding mice with an
oxalate-rich diet that was prepared by adding 50 μmol/g so-
dium oxalate to a calcium-free standard diet (Ssniff, Soest,
Germany) as previously described [22, 23]. Mice were sacri-
ficed at day 7, 14 and 21 after exposure to oxalate-rich diet.
Autologous anti-GBM glomerulonephritis model was de-
veloped by immunizing mice subcutaneously in both flanks
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with 20 μg rabbit IgG (Jackson ImmunoResearch Labora-
tories, West Grove, PA) in Freund’s complete adjuvant
(Sigma-Aldrich, Deisenhofen, Germany). Three days later,
mice received 150 μl nephrotoxic rabbit serum intraven-
ously [24]. Animals were sacrificed on day 14, 21 and
42 days after anti-GBM serum challenge. Kidney samples
were harvested for RNA isolation and histology analysis.
All experimental procedures on animals were approved by
the Regierung von Oberbayern, München, Germany, and
were performed in accordance with their guidelines and
regulations.
Quantitative real time-PCR
An equal amount of RNA (1 μg) was used to prepare
cDNA [17]. Complementary DNA was performed with
Superscript II reverse transcriptase (ThermoFisher,
Germany), 5× first-strand buffer (Thermo Fisher Germany),
DTT (Invitrogen, Germany), dNTPs (GE Healthcare,
Germany), linear acrylamide (Ambion, Germany), hexanu-
cleotide (Roche, Germany) and RNasin (Promega,
Germany). Reverse transcriptase reaction was performed
for 90 min at 42 °C then the reaction was heated at 85 °C
for 5 min using a Mastercycler pro (Eppendorf, Germany).
RN-related molecule mRNA expression in human and
mouse solid organs, as well as diseases model, were quanti-
fied by RT-PCR using GAPDH as housekeeper gene for hu-
man samples and 18 s for mouse samples as described
previously [16]. Each PCR reaction (20 μl) involved
10 × Taq Polymerase Buffer, Taq Polymerase, dNTPs, BSA,
PCR Optimizer, SYBR green dye, MgCl2, gene specific
primers and 0.2 μl of synthesized cDNA. SYBR Green Dye
fast-two step detection protocol from Light Cycler 480
(Roche, Mannheim, Germany) running program was used
for amplification. Each amplification step included initiation
step 95 °C, annealing step 60 °C and amplification step 72 °
C and was repeated 40 times. Gene-specific primers
(300 nM, Metabion, Martinsried, Germany) were used as
listed in Table 1. DdH2O was used as negative control for
target and housekeeper genes. A specific primer for each
target was designed using the primer designing tool (NCBI)
and In silico specificity screen (BLAST) was performed.
The lengths of amplicons were between 90 and 120 bp.
The kinetics of the PCR amplification (primer efficiency)
was calculated for each set of primers. The efficiency-
corrected quantification was performed automatically by
the Light Cycler 480 based on extern standard curves de-
scribing the PCR efficiencies of the target and the reference
gene [ratio = Etarget
ΔCPtarget (control − sample)/Eref
ΔCPref (control − sample)].
The high confidence algorithm was used to reduce the risk
of the false positive crossing point. All the samples which
rise above the background fluorescence (crossing point Cp
or quantification cycle Cq) between 5 and 40 cycles during
the amplification reaction were considered as detectable.
The melting curves were analyzed for every sample to
Table 1 Primers used for RT-PCR
Heading Forward Sequence (5´➔3′) Reverse Sequence (3´➔ 5′) Accession Nr. Efficiency
Human
TNF-α ATGGGCTACAGGCTTGTCACTC CTCTTCTGCCTGCTGCACTTTG NM_ 000594 1.80
LT-α TCCGTGTTTGCTCTCCAGAGCA ACACCTTCAGCTGCCCAGACTG NM_ 000595 1.8
LT-β CGTCAGAAACGCCTGTTCCTTC GGTTTCAGAAGCTGCCAGAGGA NM_ 000595 1.97
Fas-L CTGTGTGCATCTGGCTGGTAGA GGTTCTGGTTGCCTTGGTAGGA NM_000639 1.98
TRAIL AGCTGCTACTCTCTGAGGACCT TGGCAACTCCGTCAGCTCGTTA NM_003810 1.73
TWEAK TGGAGCTGTTGATTCTGGCTTCC AAAACACGGGCTCGAAGAGCGA NM_003809 2.14
4-1BBL TGGAAATCGGCAGCTACAGCCA TCTTCCTCACGCTCCGTTTCTC NM_003811 2.08
OX40-L TGATGACTGAGTTGTTCTGCACC CCTACATCTGCCTGCACTTCTC NM_003326 2.10
APP CCTTCTCGTTCCTGACAAGTGC GGCAGCAACATGCCGTAGTCAT NM_000484 2.15
Mouse
TNF-α GGTGCCTATGTCTCAGCCTCTT GCCATAGAACTGATGAGAGGGAG NM_013693 2.20
LT-α AGCCCATCCACTCCCTCAGAAG TGCTCTCCAGAGCAGTGAGTTC NM_010735 1.94
LT-β CCTGTTGTTGGCAGTGCCTATC GACGGTTTGCTGTCATCCAGTC NM_008518 2.22
Fas-L GCCACACTCCTCGGCTCTTTTT GAAGGAACTGGCAGAACTCCGT NM_010177 2.12
TRAIL TGGAGTCCCAGAAATCCTCA TCACCAACGAGATGAAGCAG NM_009425 1.95
TWEAK ACACCGTTCACCAGCAAGTCCA CTGCGCTACGACCGCCAGATT NM_013749 1.93
4-1BBL GCGTTGTGGGTAGAGGAGCAAA CCAAGTACCTTCTCCAGCATAGG NM_009404 2.06
OX40-L CTGGTAACTGCTCCTCTGAGTC GGAAGAAGACGCTAAGGCTGGT NM_009452 1.81
APP GCCAAGACATCGTCGGAGTAGT TCCGTGTGATCTACGAGCGCAT NM_177310 2.11
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detect unspecific products and primer dimers. To visualize
the similarity and differences in gene expression profiles
among the samples, hierarchical cluster analysis were per-
formed using algorithms incorporated in the open-source
software MultiExperiment Viewer (MeV) version 4.9 [25].
Differentially expressed mRNAs were screened by Volcano
Plot between log(2)(fold change) gene expression [unstan-
dardized signal] against -log(10)(p-value) from the t-test
[noise-adjusted/standardized signal] [26].
Histopathology
After sacrifice, portions of harvested kidney tissues were
fixed in 4% neutral-buffered formalin, followed by dehy-
dration in graded alcohols and embedded in paraffin.
For further analysis such as periodic acid-Schiff (PAS)
staining or immunostaining 4 μm sections were depa-
raffinized, rehydrated, transferred into citrate buffer, and
either autoclaved or microwave treated for antigen re-
trieval and processed as described [12]. For immu-
nostaining following primary antibodies were used:
Collagen1α1 (Dako, Hamburg, Germany), anti-mouse
CD3, anti-mouse F4/80 (both Serotec, Oxford, UK).
Statistics
Data were represented as mean ± standard error of the
mean (SEM). Comparisons between groups were per-
formed using non-parametric ANOVA (non-parametric;
Kruskal-Wallis test). A p-value less than 0.05 was chosen
as statistical significance.
Results
TNF superfamily ligands mRNA expressions in adult
human tissues
We quantified the mRNA expression levels of TNFSF li-
gands e.g. TNF-α, LT-α, LT-β, Fas-L (CD95-L), TNF-related
apoptosis-inducing ligand (TRAIL), TNF-related weak in-
ducer of apoptosis (TWEAK), 4-1BBL, OX40-L (CD252)
and amyloid precursor protein (APP) using qRT-PCR in
healthy human organs. Human spleen constitutively
expressed all of these ligands with higher expression of
TRAIL compared to other ligands (Fig. 1a). However, the
expression of LT-α, Fas-L, and AAP remained low (Fig. 1a).
In general, all of these ligands were expressed at higher
levels in lungs and lower levels in brain, heart, and liver.
OX40L and LT-α were expressed at higher levels in Testis.
Thymus showed very high mRNA expression levels of LT-
α, TRAIL, and 4-1BBL whereas those of LT-β and OX40-L
were only modestly increased. All these ligand expressions
in kidney were similar to spleen except for Fas-L, which
was modestly high in the kidney and 4-1BBL, which was
lower. The mRNA expression levels of most of the other
molecules were lower in the solid organs compared to
spleen. Thus, mRNA expressions of TNFSF ligands are
variable in healthy human solid organs compared to spleen.
TNF superfamily ligands mRNA expressions in adult
murine tissues
Next, we quantified the mRNA expression of the above-
mentioned TNFSF ligands in the same organs from
healthy, 10-12 weeks old, male C57BL/6 N mice. We
found that mouse spleen constitutively expressed all of
these ligands. However, the mRNA expression levels of
LT-β and AAP were higher whereas those of Fas-L,
TRAIL, and OX40L were lower in the mouse spleen
Fig. 1 TNFSF ligands mRNA expressions in adult human and murine
tissues a Quantitative real-time PCR analysis was performed on cDNAs
prepared from pools of healthy human tissue as described in the
methods and mRNA expression levels of all the organs were normalised
to GAPDH mRNA expression level and spleen mRNA levels were
illustrated in the form histograms. Whereas the mRNA expression levels
of other organs were normalized to spleen mRNA expression levels and
were represented in the heatmap. b cDNAs derived from five adult 12-
week old C57BL/6 mice as described in methods and mRNA expression
levels of all the organs were normalised to 18 s rRNA expression level
and the spleen mRNA levels were illustrated in the form of histograms.
Whereas the mRNA expression levels of respected other organs were
normalized to spleen expression levels and were represented in the
heatmap. Data represent means ± SEM
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(Fig. 1b). In sharp contrast to human organs, all mouse
organs, except thymus, expressed higher levels of AAP
(Fig. 1b). In addition, mouse spleen expressed very low
mRNA expression levels of TNFSF ligands compared to
human spleen. However, like human liver, mouse liver
also expressed very low levels of TNFSF ligands. The
mRNA expression of Fas-L was higher in thymus, lung,
heart, colon, and kidney; lower in the liver, and remained
unchanged in brain and testis compared to spleen. Lung
also expressed higher levels of TWEAK. TRAIL was
expressed at modestly high levels in lung and testis. The
latter also showed modestly higher levels of OX40-L.
The mRNA expression of other TNFSF ligands was
markedly lower in the mouse solid organs compared to
the spleen (Fig. 1b). Furthermore, we also compared the
organ-specific mRNA expression of TNFSF ligands be-
tween humans and mice and observed obvious differ-
ences between them (Fig. 2). For example, mouse brain
expressed very high mRNA levels of AAP (about 12 fold)
compared to human brain. AAP was also expressed at
higher levels in mouse kidney and lungs compared to
the human kidney and lungs, respectively. TRAIL, 4-
1BBL, and LT-α were expressed at higher levels in hu-
man thymus whereas OX40-L and LT-α were expressed
at higher levels in human testis compared to mouse
testis. Mouse heart expressed higher levels of Fas-L,
TWEAK, and AAP than the human heart. Thus, humans
and mice express different relative mRNA levels of
TNFSF ligands.
TNF superfamily ligands mRNA expressions in murine
acute kidney injury
We further studied the changes in the mRNA expression
of TNFSF ligands during transient injury using a murine
model of ischemic renal injury (IRI). The IRI model is
characterized by acute tubular necrosis and inflamma-
tion in an injury phase (day 1), which is followed by
tubular regeneration in a healing phase (day 5 and 10)
(Fig. 3a) [19–21]. We observed an increase in the infil-
tration of F4/80+ macrophages and CD3+ T cells in the
injured kidneys, which is associated with increased renal
mRNA expression levels of TNFSF ligands at day 5 and
10 (Fig. 3a). The mRNA expression levels of TRAIL,
TWEAK, as well as OX-40 L, remained unchanged at
day 1, 5 and 10 (Fig. 3b-c). The mRNA expression levels
of APP were significantly downregulated whereas that of
Fas-L and LT-α was significantly upregulated at all time
points (Fig. 3b-c). Moreover, the mRNA expression
levels of TNF-α, LT-β, and 4-1BBL were increased only
in the healing phase, at day 5 and 10 (Fig. 3b-c). There-
fore, we conclude that mRNA expressions of TNFSF li-
gands are differentially regulated during the course of a
transient injury – for example, ischemic renal injury.
TNF superfamily ligands mRNA expressions in murine
chronic kidney disease
We observed higher levels of mRNA expressions of
TNFSF ligands in healing phase after a transient renal in-
jury. Therefore, we next studied the changes in their ex-
pression during chronic tissue remodeling. We induced
chronic kidney disease (CKD) in mice by feeding them an
oxalate-rich diet for 21 days [22, 23]. Oxalate-induced
CKD was associated with a progressive increase of F4/80+
macrophages and CD3+ T cells infiltrating the renal inter-
stitial compartment as well as interstitial fibrosis from day
7 to 21 (Fig. 4a). Similar to IRI, the mRNA expression of
APP was significantly downregulated at all time points. At
day 7, mRNA expressions of TWEAK, LT-α, and OX-40 L
remained low. The later was only induced significantly at
day 14 whereas LT-α was significantly high at day 14 and
21. There were no significant differences observed in the
mRNA expression of TRAIL in oxalate-induced CKD.
However, mRNA expression levels of 4-1BBL, TNF-α, and
LT-β were significantly higher at day 7, 14, and 21. In
contrast, the mRNA expression of Fas-L significantly
decreased in a time-dependent manner during the pro-
gression of oxalate-induced CKD (Fig. 4b-c). Thus, the
mRNA expressions of TNFSF ligands are also differen-
tially regulated during chronic kidney remodeling in
oxalate-induced CKD.
TNF superfamily ligands mRNA expressions in chronic
immune complex glomerulonephritis
TNFSF ligands play an important role in the pathogen-
esis of immune complex organ injuries [27]. Therefore,
we studied the changes in their mRNA expression levels
during an immune complex glomerulonephritis. We
used an animal model of autologous anti-GBM nephritis
and checked the expression of TNFSF ligands at day 14,
21, and 42 [28]. Immune complex glomerulonephritis
was associated with a progressive increase in glomeruli
with global lesions, as well as renal interstitial infiltration
of F4/80+ macrophages and CD3+ T cells (Fig. 5a). Un-
like, IRI and oxalate-induced CKD, the mRNA expres-
sion of LT-β remained low at all time points during the
progression of immune complex glomerulonephritis
(Fig. 5b-c). We observed a transient increase in the
mRNA expression levels of TRAIL at day 21 (Fig. 5b-c).
On the contrary, expression of 4-1BBL and TNF-α were
significantly higher whereas APP expression was signifi-
cantly lower at day 14, 21 and 42 (Fig. 5b-c). The mRNA
expression of all other ligands was significantly higher
during immune complex glomerulonephritis progres-
sion; however, TWEAK and LT-α induction was not
statistically significant in the later phase at day 42
(Fig. 5b-c). Together, we observed sharp differences in
kidney remodeling induced by persistent crystal injury
and immune complex mediated injury.
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Discussion
The TNFSF ligands exert pleiotropic effects [11]. Al-
though they evolved mainly for the regulation of im-
mune cells in our body, over the years they have been
reported to be involved in several pathogenic disorders
as well. Here, our data demonstrate that alike PRRs [14],
CLRs [16], TLR accessory molecules [15], and regulated
necrosis-related molecules [18], the relative mRNA
expression profiles of TNFSF ligands differ between
physiological conditions in humans and mice, as well as
between various pathophysiological conditions in mice.
All TNFSF ligands activate NF-ĸB signalling, albeit to dif-
ferent extent, therefore, the pathologies related to them
mostly involve NF-ĸB signalling-mediated inflammation,
for example – acute IRI. Several studies have reported the
contribution of TNFSF ligands e.g. Fas-L, TWEAK and
TNF-α, which are secreted by infiltrating immune cells, to
intrarenal inflammation during IRI [29–32]. Accordingly,
we observed a robust increase in the mRNA expression
levels of TNFSF ligands after IRI that was also associated
with increased intrarenal immune cell infiltration. Recently,
TWEAK mRNA expressions were also reported to be in-
creased in various mouse models of CKD such as lupus
nephritis, immune complex glomerulonephritis, as well as
rat and human diabetic nephropathy [32]. On the contrary,
although TRAIL mRNA expression was increased at day 1
after IRI [27], we did not observe changes in the TRAIL
mRNA expression at later time points in our study. More-
over, we observed that the expression levels of TNFSF li-
gands were highest during the healing phase after IRI,
Fig. 2 Comparison of expression profiles of TNFSF ligands in human and mice. The respective relative human (white bars) and murine (black
bars) and TNFSF ligands mRNA expression levels from Fig. 1 are illustrated. The x-axis shows mRNA expression levels of the organs normalized to
spleen mRNA expression levels of the respective species. The y-axis marks the fold-change in each direction. Note that the scale of the y-axis is
different for each organ. Data represent means ± SEM
Devarapu et al. Journal of Biomedical Science  (2017) 24:77 Page 6 of 11
suggesting their putative involvement during tubule regen-
eration after an injury [33]. It may therefore interesting to
explore whether TNFSF ligands contribute to regeneration/
healing process upon acute kidney injury IRI.
Different functional states of immune cells regulate the
process of regeneration upon kidney injury. Persistent in-
flammation is deleterious since it promote chronic tissue
remodelling (fibrosis) [33]. We studied progressive kidney
fibrosis using a murine model of oxalate-induced CKD.
Although, we observed a robust increase in the mRNA
expression levels of most TNFSF ligands in association
with infiltrating immune cells, the expression patterns in
progressive kidney injury were different from transient
kidney injury observed in the IRI model. This suggests
that different pathologies are driven by different TNFSF li-
gands. Interestingly, the injection of recombinant murine
TNF-α in mice increased the expressions of TNF recep-
tors (TNFRs) in the kidney [34]. Accordingly, the in-
creased mRNA expression of TNF-α in kidneys of mice
exposed to oxalate-rich diet can be linked to the already
Fig. 3 TNFSF ligands mRNA expressions in murine ischemic renal injury. IRI was induced in C57Bl6 mice as described in methods. a Representative
images of renal sections stained with PAS or for F4/80 and CD3. Original magnification: ×100. The tubular injury, as well as F4/80 and CD3 positive area
per hpf, were quantified. Data represents mean ± s.e.m. *p < 0.05, **p < 0.01, *p < 0.001. b Quantitative RTPCR was performed on cDNAs derived from
the injured kidneys. The mRNA expression levels were normalised to 18 s rRNA expression level. The heatmap represents the relative expression of
mRNA levels at day 1, 5 and 10 versus control. c The statistical analysis of TNFSF ligands mRNA expression levels in the injured kidneys at day 1, 5 and
10 versus control kidneys is represented using volcano graphs. P < 0.05 is considered statistically significant. Dotted line represent p = 0.05
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reported increased expression of TNFRs on tubular epi-
thelium during the progression of oxalate-induced CKD
[23]. TNFR induction supports the adhesion of calcium
oxalate crystals to tubular epithelium and hence nephro-
calcinosis eventually leading to CKD [23]. Moreover,
TNF-α has also been reported to contribute to the patho-
genesis of other forms of CKD – for example, diabetic
nephropathy, Alport glomerulosclerosis, and chronic is-
chemic renal injury [35–37]. Therefore, it will be interes-
ting to study the functional contribution of each of the
Fig. 4 TNFSF ligands mRNA expressions in murine oxalate-induced CKD. Oxalate-induced CKD was induced in mice as described in methods.
a Representative images of renal sections stained with PAS or for F4/80, CD3 and collagen1. Original magnification: ×100. The tubular injury, F4/
80, CD3 positive cells, and collagen-1 were quantified. Data represents mean ± s.e.m. *p < 0.05, **p < 0.01, *p < 0.001. b Quantitative RTPCR was
performed on cDNAs derived from the kidneys of mice on day 7, 14 and 21. The mRNA expression levels were normalised to 18 s rRNA expression
level. The heatmap represents the relative expression of TNFSF ligands mRNA levels at day 7, 14 and 21versus day 0. c The statistical analysis of TNFSF
ligands mRNA expression levels in the kidneys at day 7, 14 and 21 versus day 0 is represented using volcano graphs. P < 0.05 is considered statistically
significant. Dotted line represent p = 0.05
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other induced TNFSF ligands, as well as their receptors,
during the progression of CKD.
In addition to the persistent trigger, chronic inflam-
mation can also arise from tissue deposition of immune
complex [38]. Surprisingly, unlike transient and persis-
tent injuries, immune complex injury showed sharp dif-
ferences in the mRNA expression patterns of TNFSF
ligands, which did not at all correlate with the in-
creased renal infiltration of immune cells. This suggests
that the different pathomechanisms alter the mRNA ex-
pression of TNFSF ligands. Nevertheless, we observed a
robust increase in the mRNA expression of TWEAK
and TNF-α in the early phase, which was already shown
to contribute to the disease pathology in mice, as well
as human, kidney disease [32, 39–41]. Therefore, it
would be interesting to study the specific contribution
of all the induced genes in immune complex mediated
renal injuries.
Fig. 5 TNFSF ligands mRNA expressions in murine autologous anti-GBM nephritis. Autologous anti-GBM nephritis was induced in mice as described in
methods. a Representative images of renal sections stained with PAS or for F4/80 and CD3. Original magnification: ×100. The glomerulosclerosis, F4/80,
and CD3 positive cells were quantified. Data represents mean ± s.e.m. *p < 0.05, **p < 0.01, *p < 0.001. b Quantitative RTPCR was performed on cDNAs
derived from the kidneys of mice on day 0, 14, 21 and 42. TNFSF ligands mRNA expression levels were normalised to 18 s rRNA expression levels. The
heatmap represents the relative expression of TNFSF ligands mRNA levels at day 0, 14, 21 and 42 versus day 0. c The statistical analysis of TNFSF ligands
mRNA expression levels in the kidneys at day 5, 10 and 35 versus control is represented using volcano graphs. P < 0.05 is considered statistically
significant. Dotted line represent p = 0.05
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Furthermore, as TNFSF receptors mediate the effects
of TNFSF ligands, the contribution of TNFSF ligands to
disease pathologies also depend on TNFSF receptor ex-
pressions [3, 23, 42]. Hence, studying the organ- and
species differences in expression of TNFSF receptors
along with TNFSF ligands during health and disease
conditions deserves careful consideration.
Conclusions
We identified several TNFSF ligands that are induced
during ischemic CKD, crystalline CKD, as well as im-
mune complex glomerulonephritis. In addition, we have
identified significant differences in the mRNA expression
profiles of the TNFSF ligands in humans and murine
solid organs during physiological conditions. Therefore,
our data give robust reasons to consider these species-
specific differences of TNFSF ligands in order to avoid
the misinterpretation and wrong conclusions during data
extrapolation between species. Since TNF-based thera-
peutics are already approved for human use, and several
more are likely to be found in the future based on
TNFSF ligands, the findings of our study recommend
validating results of rodent studies, not only kidney dis-
eases but also other pathogenic disorders, in human
studies.
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